Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, discusses the outcomes of the ReDOS study and whether physicians should feel comfortable using dose escalation of Stivarga (regorafenib) in their practice

Published: 20 January 2018

Recent Videos

video

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, considers the ...

video

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, shares thoughts ...

video

Kenneth Wang, MD, on how to assess response in esophageal cancer and utilize the information

Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, offers opinion on ...

video

Kenneth Wang, MD, on managing esophageal cancer patients who have completed neoadjuvant therapy

Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, describes how he ...

video

Kenneth Wang, MD, offers opinion on approaches to treating esophageal cancer

Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, tells us what ...

video

Khaldoun Almhanna, MD, MPH, discusses the risk factors to watch for gastroesophageal cancer

Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, elaborates on ...

video

Khaldoun Almhanna, MD, MPH, offers opinion on the best way to manage early gastric cancer

Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, considers the ...

video

Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients

Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, explains how we diagnose and assess response in ...

video

Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018

Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, elaborates on the latest in systemic therapy for ...

video

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, discusses the ...

Related Videos

video-image

Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients

video-image

Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018

video-image

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

video-image

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients

video-image

Kenneth Wang, MD, on how to assess response in esophageal cancer and utilize the information

video-image

Kenneth Wang, MD, on managing esophageal cancer patients who have completed neoadjuvant therapy

video-image

Kenneth Wang, MD, offers opinion on approaches to treating esophageal cancer

video-image

Khaldoun Almhanna, MD, MPH, discusses the risk factors to watch for gastroesophageal cancer

video-image

Khaldoun Almhanna, MD, MPH, offers opinion on the best way to manage early gastric cancer

video-image

Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer

video-image

Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved

video-image

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

video-image

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

video-image

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated